SYBX - רווח לפני ריבית, מסים ופחת Synlogic

Synlogic, Inc. (SYBX) develops synthetic biologics for metabolic correction in US laboratories. The base EBITDA reflects pre-tax cash flow dynamics, where the 0.00 indicator determines the metric's value. Revenue prospects relied on the commercialization of modified probiotics, but the ecosystem has now been completely destroyed, and asset liquidation has led to the final closure of the business.

Investors must monitor the actual liquidity of Synlogic, Inc. (SYBX), as laboratory equipment supply chain disruptions can instantaneously drain operating cash flow. Analyzing aggregate EBITDA allows for the identification of hidden cash shortages prior to the publication of reports, separating actual cash inflows from accounting profits and warning of business leverage risks.